longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Hyperion DeFi

HYPD

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -3.41, below the reasonable range, cheaper than 99.62% of the time in the past 1 years, and the industry ranks 147/257, the industry Median -1.31.

-3.41xP/E
$3.92Stock price
$-1.15Earnings per share
-3.41xP/E
Stock price$3.92Earnings per share$-1.15

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.03x
Typical range
-1.28x–-0.84x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-57.21x14.24%$59.74B
BAYZFUSBayer Aktiengesellschaft
-26.78x--$54.03B
BAYRYUSBayer
-26.80x--$54.07B
VTRSUSViatris
-47.40x110.35%$19.47B
ELANUSElanco Animal Health
-56.29x129.36%$11.20B
VREOFUSVIREO GROWTH INC
-162.76x--$10.92B
AXSMUSAxsome Therap
-56.79x27.32%$10.88B
CURLFUSCuraleaf Holdings, Inc.
-154.04x--$8.01B
BLTEUSBelite Bio
-67.26x29.87%$6.88B
DFTXUSDefinium Therapeutics
-14.74x53.32%$5.21B
EWTXUSEdgewise Therapeutics
-24.96x137.29%$4.92B
MANEUSVeraDermics
-42.77x97.39%$4.46B
AMLXUSAmylyx Pharmaceuticals
-26.75x1.76%$4.07B
ELVNUSEnliven Therapeutics
-34.21x1.17%$3.62B
TARSUSTarsus Pharmaceuticals
-73.73x34.09%$3.43B
MBXUSMBX Biosciences
-29.05x30.54%$3.03B
RGCUSRegencell Bioscience
-407.00x--$2.87B
PHVSUSPharvaris BV
-12.87x7.70%$2.55B
GPCRUSStructure Therapeutics
-11.62x104.48%$2.50B
SUPNUSSupernus Pharma
-22.22x70.59%$2.44B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.